@article {Zamek-Gliszczynski1109, author = {Maciej J. Zamek-Gliszczynski and David Kenworthy and David A. Bershas and Mitesh Sanghvi and Adrian I. Pereira and Jennypher Mudunuru and Lee Crossman and Jill L. Pirhalla and Karl M. Thorpe and Jeremy M.T.J. Dennison and Megan M. McLaughlin and Matthew Allinder and Brandon Swift and Robin L. O{\textquoteright}Connor-Semmes and Graeme C. Young}, title = {Pharmacokinetics and ADME Characterization of Intravenous and Oral [14C]-Linerixibat in Healthy Male Volunteers}, volume = {49}, number = {12}, pages = {1109--1117}, year = {2021}, doi = {10.1124/dmd.121.000595}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Linerixibat, an oral small-molecule ileal bile acid transporter inhibitor under development for cholestatic pruritus in primary biliary cholangitis, was designed for minimal absorption from the intestine (site of pharmacological action). This study characterized the pharmacokinetics, absorption, metabolism, and excretion of [14C]-linerixibat in humans after an intravenous microtracer concomitant with unlabeled oral tablets and [14C]-linerixibat oral solution. Linerixibat exhibited absorption-limited flip-flop kinetics: longer oral versus intravenous half-life (6{\textendash}7 hours vs. 0.8 hours). The short intravenous half-life was consistent with high systemic clearance (61.9 l/h) and low volume of distribution (16.3 l). In vitro studies predicted rapid hepatic clearance via cytochrome P450 3A4 metabolism, which predicted human hepatic clearance within 1.5-fold. However, linerixibat was minimally metabolized in humans after intravenous administration: \~{}80\% elimination via biliary/fecal excretion (\>90\%{\textendash}97\% as unchanged parent) and \~{}20\% renal elimination by glomerular filtration (\>97\% as unchanged parent). Absolute oral bioavailability of linerixibat was exceedingly low (0.05\%), primarily because of a very low fraction absorbed (0.167\%; fraction escaping first-pass gut metabolism (fg) \~{}100\%), with high hepatic extraction ratio (77.0\%) acting as a secondary barrier to systemic exposure. Oral linerixibat was almost entirely excreted (\>99\% recovered radioactivity) in feces as unchanged and unabsorbed linerixibat. Consistent with the low oral fraction absorbed and \~{}20\% renal recovery of intravenous [14C]-linerixibat, urinary elimination of orally administered radioactivity was negligible (\<0.04\% of dose). Linerixibat unequivocally exhibited minimal gastrointestinal absorption and oral systemic exposure. Linerixibat represents a unique example of high CYP3A4 clearance in vitro but nearly complete excretion as unchanged parent drug via the biliary/fecal route.Significance Statement This study conclusively established minimal absorption and systemic exposure to orally administered linerixibat in humans. The small amount of linerixibat absorbed was eliminated efficiently as unchanged parent drug via the biliary/fecal route. The hepatic clearance mechanism was mispredicted to be mediated via cytochrome P450 3A4 metabolism in vitro rather than biliary excretion of unchanged linerixibat in vivo.}, issn = {0090-9556}, URL = {https://dmd.aspetjournals.org/content/49/12/1109}, eprint = {https://dmd.aspetjournals.org/content/49/12/1109.full.pdf}, journal = {Drug Metabolism and Disposition} }